24 related articles for article (PubMed ID: 29781825)
1. Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study.
Li XL; Liu ZP; Su XX; Gong Y; Yang YS; Zhao XL; Li ZM; Ding JJ; Zhu Y; Yin DL; Yu C; Zhou JX; Zhang D; Ding R; Chen W; Cheng Y; Yue P; Wang ZR; Zhang YQ; Jiang Y; Yin XY; Bai J; Dai HS; Lau WY; Chen ZY;
Int J Surg; 2024 Apr; 110(6):3580-90. PubMed ID: 38626431
[TBL] [Abstract][Full Text] [Related]
2. Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer.
Maehana T; Kawaguchi R; Nishikawa K; Kawahara N; Yamada Y; Kimura F
Oncol Lett; 2024 Jul; 28(1):302. PubMed ID: 38774455
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Preoperative and Postoperative Evaluation of Combined Tumor Markers for Patients With Colon Cancer.
Pan HF; Zheng ZF; Zhao ZY; Liu Z; Huang SH; Chi P
Surg Laparosc Endosc Percutan Tech; 2024 May; ():. PubMed ID: 38736427
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers.
Kumar VR; Kampan NC; Abd Aziz NH; Teik CK; Shafiee MN; Menon PS
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067311
[TBL] [Abstract][Full Text] [Related]
5. Effect of bevacizumab plus paclitaxel and carboplatin regimen on prognostic survival of ovarian cancer patients.
Jiang Q; Qian H; Mei L; Sun Q; Cheng X; Huang W; Xia M; Shao J; Wang J
Am J Transl Res; 2022; 14(12):8761-8767. PubMed ID: 36628241
[TBL] [Abstract][Full Text] [Related]
6. Frequency of thoracic recurrence based on pathological features in patients with ovarian epithelial tumors in stage I versus higher stages.
Matsutani H; Nakai G; Fujiwara S; Takahashi S; Yamamoto K; Ohmichi M; Osuga K
Jpn J Radiol; 2023 May; 41(5):500-509. PubMed ID: 36575285
[TBL] [Abstract][Full Text] [Related]
7. Extremely high serum CA19-9 level along with elevated D-dimer in assisting detection of ruptured ovarian endometriosis.
Shuang T; Wang Y; Zhao L; Zhang K; Yin P; Guo L; Jing W; Feng X; Li Q
Ann Med; 2022 Dec; 54(1):1444-1451. PubMed ID: 35733415
[TBL] [Abstract][Full Text] [Related]
8. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
Goh SK; Gold G; Christophi C; Muralidharan V
ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma.
Zhu J; Jiang L; Wen H; Bi R; Wu X; Ju X
Int J Gynecol Cancer; 2018 Jul; 28(6):1108-1116. PubMed ID: 29781825
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
[TBL] [Abstract][Full Text] [Related]
11. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder.
Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S
Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660
[TBL] [Abstract][Full Text] [Related]
12. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
